ATE406166T1 - Verfahren zur prävention von gewichtszunahme infolge von antipsychotika - Google Patents

Verfahren zur prävention von gewichtszunahme infolge von antipsychotika

Info

Publication number: ATE406166T1
Authority: AT; Austria
Prior art keywords: weight gain; receptor antagonist; glucocorticoid receptor; antipsychotics; result
Prior art date: 2001-07-23

Application number

AT02750269T

Other languages

English (en)

Inventor

Joseph Belanoff

Alan Schatzberg

Original Assignee

Corcept Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-23

Filing date

2002-07-22

Publication date

2008-09-15

2002-07-22 Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc

2008-09-15 Application granted granted Critical

2008-09-15 Publication of ATE406166T1 publication Critical patent/ATE406166T1/de

Links

230000004584 weight gain Effects 0.000 title abstract 3
235000019786 weight gain Nutrition 0.000 title abstract 3
239000000164 antipsychotic agent Substances 0.000 title 1
229940005529 antipsychotics Drugs 0.000 title 1
229940126013 glucocorticoid receptor antagonist Drugs 0.000 abstract 3
239000003850 glucocorticoid receptor antagonist Substances 0.000 abstract 3
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
230000000561 anti-psychotic effect Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
229960000890 hydrocortisone Drugs 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
239000000463 material Substances 0.000 abstract 1
VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 abstract 1
229960003248 mifepristone Drugs 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
102000005962 receptors Human genes 0.000 abstract 1
108020003175 receptors Proteins 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Child & Adolescent Psychology (AREA)
Psychiatry (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)

AT02750269T 2001-07-23 2002-07-22 Verfahren zur prävention von gewichtszunahme infolge von antipsychotika ATE406166T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US30769301P	2001-07-23	2001-07-23

Publications (1)

Publication Number	Publication Date
ATE406166T1 true ATE406166T1 (de)	2008-09-15

Family

ID=23190816

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02750269T ATE406166T1 (de)	2001-07-23	2002-07-22	Verfahren zur prävention von gewichtszunahme infolge von antipsychotika

Country Status (19)

Country	Link
US (1)	US6680310B2 (de)
EP (1)	EP1408981B1 (de)
JP (2)	JP2004537563A (de)
KR (1)	KR20040028942A (de)
CN (2)	CN1547473A (de)
AT (1)	ATE406166T1 (de)
AU (1)	AU2002319665B2 (de)
BR (1)	BR0211365A (de)
CA (1)	CA2454339C (de)
CY (1)	CY1108562T1 (de)
DE (1)	DE60228579D1 (de)
DK (1)	DK1408981T3 (de)
ES (1)	ES2312598T3 (de)
IL (1)	IL159913A0 (de)
MX (1)	MXPA04000692A (de)
NZ (1)	NZ530724A (de)
PT (1)	PT1408981E (de)
WO (1)	WO2003009853A1 (de)
ZA (1)	ZA200400444B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1556708A (zh) *	2001-08-31	2004-12-22	�Ƹ��	抑制成年唐氏综合症患者认知退化的方法
NZ527142A (en) *	2003-07-23	2006-03-31	Douglas Pharmaceuticals Ltd	A stable suspension formulation
GB0400031D0 (en)	2004-01-03	2004-02-04	Univ Sheffield	Depression treatment
US20050171088A1 (en) *	2004-01-30	2005-08-04	Astrazeneca Ab	Treatment of psychoses with dibenzothiazepine antipsychotic
US20060211667A1 (en) *	2005-03-21	2006-09-21	Eric Marchewitz	Use of pregnane steroid derivatives for enhancing physical performance
WO2007067714A2 (en) *	2005-12-08	2007-06-14	The Mclean Hospital Corporation	Treatment of sequelae of psychiatric disorders
WO2008128166A1 (en) *	2007-04-13	2008-10-23	Concert Pharmaceuticals Inc.	Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
US10500216B2 (en)	2011-11-18	2019-12-10	Corcept Therapeutics, Inc.	Optimizing mifepristone absorption
US8859774B2 (en)	2012-05-25	2014-10-14	Corcept Therapeutics, Inc.	Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12226412B2 (en)	2012-05-25	2025-02-18	Corcept Therapeutics, Inc.	Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
EP4219494B1 (de)	2013-11-25	2026-03-25	Corcept Therapeutics Incorporated	Octahydrokondensierte azadekalin-glucocorticoid-rezeptor-modulatoren
US9943526B2 (en)	2015-04-21	2018-04-17	Corcept Therapeutics, Inc.	Optimizing mifepristone levels for cushing's patients
SG11201908790PA (en)	2017-03-31	2019-10-30	Corcept Therapeutics Inc	Glucocorticoid receptor modulators to treat cervical cancer
US11273166B2 (en)	2017-06-13	2022-03-15	Monash University	Methods and compositions for the treatment of obesity
AU2019404026B2 (en)	2018-12-19	2023-06-08	Corcept Therapeutics Incorporated	Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
WO2020132046A1 (en)	2018-12-19	2020-06-25	Corcept Therapeutics Incorporated	Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11234971B2 (en)	2018-12-19	2022-02-01	Corcept Therapeutics Incorporated	Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CA3131263C (en)	2019-02-22	2024-01-02	Corcept Therapeutics Incorporated	Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
AU2020239920A1 (en)	2019-03-18	2021-11-04	Arnold L. Newman	Method of improving insulin sensitivity
US11903945B2 (en) *	2019-12-11	2024-02-20	Corcept Therapeutics Incorporated	Methods of treating antipsychotic-induced weight gain with miricorilant
WO2021226258A1 (en)	2020-05-06	2021-11-11	Corcept Therapeutics Incorporated	Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
KR20230017829A (ko)	2020-05-27	2023-02-06	코어셉트 쎄라퓨틱스 인코포레이티드	글루코코르티코이드 수용체 조절제 렐라코릴란트 및 cyp2c8과 cyp3a4의 이중 기질인 파클리탁셀의 병용 투여
WO2022134033A1 (en)	2020-12-25	2022-06-30	Corcept Therapeutics Incorporated	Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12616698B2 (en)	2021-05-05	2026-05-05	Corcept Therapeutics Incorporated	Methods for reducing liver fat and for treating fatty liver disorders
WO2024077169A1 (en)	2022-10-06	2024-04-11	Corcept Therapeutics Incorporated	Formulations of glucocorticoid receptor modulators
US12433882B2 (en)	2022-10-28	2025-10-07	Corcept Therapeutics Incorporated	Treatments for amyotrophic lateral sclerosis using dazucorilant

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2757400B1 (fr) *	1996-12-19	1999-12-17	Hoechst Marion Roussel Inc	Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs
US5929058A (en)	1996-12-24	1999-07-27	Zymogenetics, Inc.	Treatment agents and methods for treating type II diabetes and symptoms of type II diabetes
CN1187053C (zh)	1997-10-06	2005-02-02	利兰·斯坦福青年大学托管委员会	糖皮质素受体拮抗剂用于制造治疗精神病药物的用途
IL139672A (en)	1998-05-15	2005-11-20	Univ Leland Stanford Junior	Glucocorticoid receptor antagonists for the tretment of dementia
EP1223939A1 (de) *	1999-05-19	2002-07-24	AstraZeneca AB	Verfahren zur behandlung der gewichtszunahme

2002
- 2002-07-22 JP JP2003515245A patent/JP2004537563A/ja active Pending
- 2002-07-22 CN CNA028166647A patent/CN1547473A/zh active Pending
- 2002-07-22 NZ NZ530724A patent/NZ530724A/en not_active IP Right Cessation
- 2002-07-22 CA CA2454339A patent/CA2454339C/en not_active Expired - Fee Related
- 2002-07-22 AT AT02750269T patent/ATE406166T1/de active
- 2002-07-22 MX MXPA04000692A patent/MXPA04000692A/es active IP Right Grant
- 2002-07-22 CN CNA2005101236436A patent/CN1853722A/zh active Pending
- 2002-07-22 US US10/201,356 patent/US6680310B2/en not_active Expired - Lifetime
- 2002-07-22 AU AU2002319665A patent/AU2002319665B2/en not_active Ceased
- 2002-07-22 WO PCT/US2002/023441 patent/WO2003009853A1/en not_active Ceased
- 2002-07-22 ES ES02750269T patent/ES2312598T3/es not_active Expired - Lifetime
- 2002-07-22 BR BR0211365-1A patent/BR0211365A/pt not_active Application Discontinuation
- 2002-07-22 DK DK02750269T patent/DK1408981T3/da active
- 2002-07-22 KR KR10-2004-7001039A patent/KR20040028942A/ko not_active Ceased
- 2002-07-22 DE DE60228579T patent/DE60228579D1/de not_active Expired - Lifetime
- 2002-07-22 EP EP02750269A patent/EP1408981B1/de not_active Expired - Lifetime
- 2002-07-22 PT PT02750269T patent/PT1408981E/pt unknown
- 2002-07-22 IL IL15991302A patent/IL159913A0/xx not_active IP Right Cessation
2004
- 2004-01-21 ZA ZA2004/00444A patent/ZA200400444B/en unknown
2008
- 2008-11-12 CY CY20081101296T patent/CY1108562T1/el unknown
2009
- 2009-02-03 JP JP2009023156A patent/JP2009102413A/ja active Pending

Also Published As

Publication number	Publication date
ES2312598T3 (es)	2009-03-01
ZA200400444B (en)	2005-03-30
AU2002319665B2 (en)	2006-09-21
PT1408981E (pt)	2008-12-04
JP2004537563A (ja)	2004-12-16
HK1061526A1 (en)	2004-09-24
MXPA04000692A (es)	2004-04-21
CN1853722A (zh)	2006-11-01
EP1408981A1 (de)	2004-04-21
CN1547473A (zh)	2004-11-17
KR20040028942A (ko)	2004-04-03
US6680310B2 (en)	2004-01-20
DK1408981T3 (da)	2009-01-12
DE60228579D1 (de)	2008-10-09
BR0211365A (pt)	2004-09-21
NZ530724A (en)	2005-09-30
CA2454339A1 (en)	2003-02-06
JP2009102413A (ja)	2009-05-14
US20030027802A1 (en)	2003-02-06
CA2454339C (en)	2012-01-10
EP1408981B1 (de)	2008-08-27
CY1108562T1 (el)	2014-04-09
IL159913A0 (en)	2004-06-20
WO2003009853A1 (en)	2003-02-06
EP1408981A4 (de)	2005-06-08

Publication	Publication Date	Title
CY1108562T1 (el)	2014-04-09	Μεθοδοι για την προληψη προσληψης βαρους η οποια προκαλειται απο αντιψυχωτικες θεραπειες
ATE317699T1 (de)	2006-03-15	Glucocorticoid receptor antagonisten zur behandlung von demenz
WO2002076390A3 (en)	2003-05-22	Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
DE69835225D1 (de)	2006-08-24	Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen
ATE498395T1 (de)	2011-03-15	Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
HRP20181459T1 (hr)	2018-10-19	Humanizirani antagonisti anti-beta7 i njihove uporabe
ATE507210T1 (de)	2011-05-15	Chinazolinon modulatoren von nukleinrezeptoren
WO2004058717A8 (en)	2004-08-19	Isoquinolinone derivatives and their use as therapeutic agents
SG155054A1 (en)	2009-09-30	Human anti- neutralizing antibodies as selective pathway inhibitors
UA89734C2 (en)	2010-02-25	ANTAGONISTS of muscarinic acetylcholine receptors
NO20003534D0 (no)	2000-07-07	Progesteronreseptor-modulatorforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsene
ATE450251T1 (de)	2009-12-15	Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
ATE411013T1 (de)	2008-10-15	Verfahren zur hemmung der verschlechterung der kognitiven leistungsfähigkeit bei erwachsenen mit down-syndrom
HK1047050A1 (zh)	2003-02-07	治疗轻度智力机能缺陷的方法
ATE529116T1 (de)	2011-11-15	Verfahren zur verstärkung des therapeutischen ansprechens auf elektrokonvulsive therapie (ect)
WO2004069202A3 (en)	2005-01-06	Antiglucocorticoids for the treatment of postpartum psychosis
ATE492281T1 (de)	2011-01-15	Verwendung von glucocorticoid-rezeptor- spezifischen antagonisten zur behandlung von delirium
WO2002020526A3 (en)	2002-05-30	Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents
DK1165184T3 (da)	2004-04-13	Estrogenreceptor-beta antagonisme og knoglesygdomme
EP1726307A3 (de)	2007-04-04	Methode zur Behandlung von durch Glycocorticoidstörungen verursachten Psychosen